Alpha Anomeric Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Alpha Anomeric General Information
Description
Developer of genetic medicines intended to provide the precision tools to modulate new ribonucleic acid (RNA) targets and neuromuscular diseases. The company's medicines are developed by a proprietary alpha anomeric-bicyclo DNA platform that reaches unprecedented precision in RNA modulation by eliminating common side effects of current oligonucleotide chemistries and by increasing the specificity and effectiveness of treatment, enabling physicians to treat patients with severe neuromuscular diseases.
Contact Information
Website
www.alpha-anomeric.com(Operating Subsidiary)
Corporate Office
- 140 Bis, Rue De Rennes
- 75006 Paris
- France
Corporate Office
- 140 Bis, Rue De Rennes
- 75006 Paris
- France
Alpha Anomeric Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 29-Apr-2025 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 30-Sep-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 14-Feb-2019 | $1.71M | $1.71M | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Feb-2018 | Completed | Generating Revenue |
Alpha Anomeric Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Alpha Anomeric Patents
Alpha Anomeric Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021382146-A1 | Nucleic acid duplexes | Pending | 23-Nov-2020 | ||
| AU-2021382146-A9 | Nucleic acid duplexes | Pending | 23-Nov-2020 | ||
| CA-3202708-A1 | Nucleic acid duplexes | Pending | 23-Nov-2020 | ||
| EP-4247949-A1 | Nucleic acid duplexes | Pending | 23-Nov-2020 | ||
| US-20240002853-A1 | Nucleic acid duplexes | Pending | 23-Nov-2020 | C12N15/113 |
Alpha Anomeric Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent Life Sciences | Venture Capital | Minority | ||
| University of Bern | University |
Alpha Anomeric FAQs
-
When was Alpha Anomeric founded?
Alpha Anomeric was founded in 2018.
-
Where is Alpha Anomeric headquartered?
Alpha Anomeric is headquartered in Paris, France.
-
What industry is Alpha Anomeric in?
Alpha Anomeric’s primary industry is Drug Discovery.
-
Is Alpha Anomeric a private or public company?
Alpha Anomeric is a Private company.
-
What is Alpha Anomeric’s current revenue?
The current revenue for Alpha Anomeric is .
-
How much funding has Alpha Anomeric raised over time?
Alpha Anomeric has raised $5.24M.
-
Who are Alpha Anomeric’s investors?
Advent Life Sciences and University of Bern have invested in Alpha Anomeric.
-
When was Alpha Anomeric acquired?
Alpha Anomeric was acquired on 29-Apr-2025.
-
Who acquired Alpha Anomeric?
Alpha Anomeric was acquired by AlphaRose Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process